NO20032769L - Kombinasjonsmetode for behandling av virale infeksjoner - Google Patents

Kombinasjonsmetode for behandling av virale infeksjoner

Info

Publication number
NO20032769L
NO20032769L NO20032769A NO20032769A NO20032769L NO 20032769 L NO20032769 L NO 20032769L NO 20032769 A NO20032769 A NO 20032769A NO 20032769 A NO20032769 A NO 20032769A NO 20032769 L NO20032769 L NO 20032769L
Authority
NO
Norway
Prior art keywords
treatment
viral infections
combination method
combination
infections
Prior art date
Application number
NO20032769A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032769D0 (no
Inventor
Bahige M Baroudy
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20032769D0 publication Critical patent/NO20032769D0/no
Publication of NO20032769L publication Critical patent/NO20032769L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Peptides Or Proteins (AREA)
NO20032769A 2000-12-19 2003-06-18 Kombinasjonsmetode for behandling av virale infeksjoner NO20032769L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25665700P 2000-12-19 2000-12-19
PCT/US2001/048802 WO2002056902A2 (en) 2000-12-19 2001-12-17 Ccr5 antagonist and dp-178 polypeptide for treating viral infections

Publications (2)

Publication Number Publication Date
NO20032769D0 NO20032769D0 (no) 2003-06-18
NO20032769L true NO20032769L (no) 2003-08-18

Family

ID=22973061

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032769A NO20032769L (no) 2000-12-19 2003-06-18 Kombinasjonsmetode for behandling av virale infeksjoner

Country Status (12)

Country Link
US (1) US20050065319A1 (cg-RX-API-DMAC10.html)
EP (1) EP1385534A2 (cg-RX-API-DMAC10.html)
JP (1) JP2005500981A (cg-RX-API-DMAC10.html)
CN (1) CN1481251A (cg-RX-API-DMAC10.html)
AR (1) AR031931A1 (cg-RX-API-DMAC10.html)
BR (1) BR0116253A (cg-RX-API-DMAC10.html)
CA (1) CA2431919A1 (cg-RX-API-DMAC10.html)
HU (1) HUP0302241A3 (cg-RX-API-DMAC10.html)
MX (1) MXPA03005526A (cg-RX-API-DMAC10.html)
NO (1) NO20032769L (cg-RX-API-DMAC10.html)
WO (1) WO2002056902A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200304560B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
RU2353357C2 (ru) * 2003-05-16 2009-04-27 Юниверсити Оф Мэрилэнд Байотекнолоджи Инститьют Композиции для супрессии экспрессии ccr5 и способы их применения
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
JP2009517474A (ja) * 2005-11-30 2009-04-30 シェーリング コーポレイション Ccr5拮抗剤およびcxcr4拮抗剤の組み合わせを含む組成物
WO2007065007A2 (en) * 2005-12-01 2007-06-07 Government Of The U.S.A., As Repersented By The Secretary, Dept. Of Health And Human Services Treatment of viral infections
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
CN104039815A (zh) * 2012-02-28 2014-09-10 中国人民解放军军事医学科学院毒物药物研究所 用于抑制hiv的多肽及其作用靶点
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
CN1192688A (zh) * 1995-06-07 1998-09-09 特莱默里斯公司 联合疗法治疗hiv和其它病毒性感染
US6281331B1 (en) * 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6689765B2 (en) * 1999-05-04 2004-02-10 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
PL203117B1 (pl) * 1999-05-04 2009-08-31 Schering Corp Piperydynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
WO2000066141A2 (en) * 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy

Also Published As

Publication number Publication date
EP1385534A2 (en) 2004-02-04
WO2002056902A2 (en) 2002-07-25
BR0116253A (pt) 2006-05-02
WO2002056902A3 (en) 2002-12-05
HUP0302241A3 (en) 2005-06-28
JP2005500981A (ja) 2005-01-13
MXPA03005526A (es) 2003-10-06
ZA200304560B (en) 2005-07-27
NO20032769D0 (no) 2003-06-18
US20050065319A1 (en) 2005-03-24
CA2431919A1 (en) 2002-07-25
CN1481251A (zh) 2004-03-10
HUP0302241A2 (hu) 2003-11-28
AR031931A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
NO20030012L (no) Fremgangsmåte for fremstilling av substituerte oktanoylamider
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20031615D0 (no) Pyrazol-derivater for behandling av virus-sykdommer
DE60136477D1 (de) Retinoide zur behandlung von emphysem
NO20040253L (no) Fremgangsmater for behandling av leverfibroser
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20040027L (no) Fremgangsmate for fremstillingen av escitalopram
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
DE60227963D1 (de) Behandlungssystem
FI20012170A0 (fi) Menetelmä lauhteiden käsittelemiseksi
NO20026219L (no) Forbindelser for behandling av svekket fundisk relaksasjon
NO20035538D0 (no) Fremgangsmåte for fremstilling av zaleplon
PT1220858E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes virais
NO20022816L (no) Behandling av virale infeksjoner ved anvendelse av Levovirin
NO20040087L (no) Fremgangsmate for behandling av sovnloshet
NO20032769D0 (no) Kombinasjonsmetode for behandling av virale infeksjoner
NO20030515L (no) Fremgangsmåte for fremstilling av dinapsolin
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DE60140597D1 (de) Vakuumbehandlungsverfahren
DK1200447T3 (da) Oxazinocarbazoler til behandling af CNS-sygdomme
NO20022253L (no) Middel til behandling av hepatitt C

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application